Status:
COMPLETED
Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis
Lead Sponsor:
Cairo University
Conditions:
Symptomatic Irreversible Pulpitis
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with...
Detailed Description
The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with...
Eligibility Criteria
Inclusion
- Patients in good health (American Society of Anesthesiologists Class I or II).
- Patients having symptomatic irreversible pulpitis in one of their mandibular molars.
- Age range between 18 to 50 years.
- Patients who can understand Numerical Rating Scale (NRS).
- Positive patient acceptance and the ability to sign an informed consent.
Exclusion
- Pregnant females.
- Patients allergic to articaine, mepivacaine and/or any used medication or material.
- Patients having active sites of pathosis in the area of injection.
- Patients having active pain in more than one molar.
- Patients who had taken analgesics in the 12 hours preceding treatment.
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT04822415
Start Date
December 1 2014
End Date
December 1 2016
Last Update
August 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.